Sorafenib

Natco Pharma's marketing partner Mylan Inc has received a tentative approval from the USFDA for abbreviated new drug application (ANDA) for Sorafenib tablets.

Natco Pharma shares surged nearly 9 per cent on Friday after the company said its marketing partner Mylan Inc has received tentative approval from the US health regulator for selling generic Sorafenib tablets, used for cancer treatment, in the American market.

A biomolecule found in saffron may potentially help treat a common form of liver cancer, a new study has claimed.

The company's marketing partner Mylan Inc has filed an abbreviated new drug application (ANDA) for Sorafenib tablets in the strength of 200mg with the US Food and Drug Administration (USFDA), Natco Pharma said in a filing to the BSE on Wednesday.

Bayer holds the patent for Nexavar till 2020 and will "vigorously defend its patent within the available legal framework".

Natco Pharma's marketing partner Mylan Inc has received a tentative approval from the USFDA for abbreviated new drug application (ANDA) for Sorafenib tablets.

Natco Pharma shares surged nearly 9 per cent on Friday after the company said its marketing partner Mylan Inc has received tentative approval from the US health regulator for selling generic Sorafenib tablets, used for cancer treatment, in the American market.

A biomolecule found in saffron may potentially help treat a common form of liver cancer, a new study has claimed.

The company's marketing partner Mylan Inc has filed an abbreviated new drug application (ANDA) for Sorafenib tablets in the strength of 200mg with the US Food and Drug Administration (USFDA), Natco Pharma said in a filing to the BSE on Wednesday.

Bayer holds the patent for Nexavar till 2020 and will "vigorously defend its patent within the available legal framework".